In particular, by retrieving the clinical information, we obtained the HER2+/−, ER+/−, and PR+/− status for 77 (out of 113) patients, corresponding to the 68% of the total number of analyzed breast cancer patients. The gene discussed is ESR1; the disease is breast cancer.